secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001683168-24-005707
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q2 net loss $1.8M, cash $4.7M; PH-762 trial progresses
------------------------------------------------------------------

- Cash at June 30, 2024: $4.7M vs $8.5M at Dec 31, 2023; net loss $1.8M vs $2.5M year ago.
- Phase 1b trial for PH-762 received positive SMC safety recommendation; dose escalation and next cohort enrollment ongoing.
- Nasdaq compliance regained for minimum $1.00 bid price after 9:1 reverse stock split effective July 5, 2024.
- Appointed Robert M. Infarinato as VP and CFO effective August 1, 2024.
- Entered exploratory collaboration with global skin care company for INTASYL cosmeceutical compounds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824005707/0001683168-24-005707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824005707/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer